---
id: ada-diabetes-standards-2025
title: "ADA Standards of Care in Diabetesâ€”2025"
short_title: "ADA Standards 2025"

organization: American Diabetes Association
collaborators: null
country: US
url: https://diabetesjournals.org/care/issue/48/Supplement_1
doi: 10.2337/dc25-S000
pmid: null
open_access: true

specialty: endocrinology
guideline_type: clinical-practice
evidence_system: ADA
conditions:
  - diabetes mellitus
  - type 1 diabetes
  - type 2 diabetes
  - gestational diabetes
tags:
  - CGM
  - GLP-1 receptor agonists
  - SGLT2 inhibitors
  - obesity management
  - immunotherapy
  - cardiovascular risk

publication_date: 2025-01-01
previous_version_date: 2024-01-01
status: current
supersedes: ada-diabetes-2024
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
The definitive 2025 annual update to the ADA Standards of Care, providing the most current evidence-based recommendations for the prevention, diagnosis, and management of all types of diabetes.

## Key Recommendations

### Diagnosis and Screening
- **Type 1 Diabetes (T1D)**: Recommends screening for T1D with islet autoantibodies in at-risk individuals to identify early stages (Stage 1 and 2) and enable early intervention (e.g., Teplizumab).
- **Type 2 Diabetes (T2D)**: Screening should begin at age 35 for all adults, and earlier in those with overweight/obesity and additional risk factors.

### Technology and Monitoring
- **Continuous Glucose Monitoring (CGM)**: Stronger emphasis on CGM for all adults with diabetes on intensive insulin therapy. 
- **Expanded CGM Use**: Now encourages the consideration of CGM for individuals with Type 2 diabetes *not* on insulin to improve self-management and glycemic awareness.

### Pharmacological Management of T2D
- **First-line Therapy**: Management should be individualized based on comorbidities, patient preferences, and social determinants of health.
- **Cardioprotection**: For patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor with proven benefit is recommended regardless of HbA1c.
- **GLP-1 Weight Benefits**: Highlights the importance of GLP-1 receptor agonists and dual GLP-1/GIP agonists (e.g., Tirzepatide) for weight management as a primary goal in T2D.

### Lifestyle and Behavioral Health
- **Resistance Training**: Recommends 2-3 sessions per week of resistance exercise to improve insulin sensitivity and muscle mass.
- **Cannabis**: Advise against recreational cannabis use in T1D due to a significantly increased risk of diabetic ketoacidosis (DKA).

### Complications and Comorbidities
- **CKD**: Finereone (nonsteroidal mineralocorticoid receptor antagonist) is recommended for patients with CKD and T2D to reduce progression and CV events.
- **NAFLD/MASLD**: Screening for liver fibrosis is recommended in patients with T2D or obesity who have elevated liver enzymes.

### Individualized Care
- Stresses the "Cycle of Care" involving shared decision-making, patient-centered language, and addressing social determinants of health (SDOH) to improve outcomes and equity.
